Molecular Imaging in Drug R&D and Medical Practice: Technologies, Applications, Markets

Table of Contents

Chapter 1 INTRODUCTION

• 1.1. Biomarker Definitions
• 1.2. Organization of the Report

Chapter 2 IN VIVO MOLECULAR IMAGING TECHNOLOGIES

• 2.1. Historical Introduction
• 2.2. Imaging Technologies
  • Computed Tomography
  • Positron Emission Tomography
  • Single Photon Emission Computed Tomography
  • Magnetic Resonance Imaging
  • Ultrasound
  • Optical Imaging
• 2.3. Combination Technologies
• 2.4. Molecular and Functional Imaging

Chapter 3 IMAGING BIOMARKERS IN DRUG DEVELOPMENT

• 3.1. Preclinical Development
• 3.2. Clinical Development
• 3.3. Therapeutic Areas
  • Cancer
    • Cell Proliferation or Metabolism
    • Apoptosis
    • Angiogenesis
    • Hypoxia
    • Other Parameters
  • Neurological Disease
    • Alzheimer' s Disease
    • Parkinson' s Disease
  • Cardiovascular Disease
  • Inflammatory and Autoimmune Disease

Chapter 4 MOLECULAR IMAGING IN DIAGNOSTICS

• 4.1. Cancer
• 4.2. Cardiovascular Disease
• 4.3. Neurological Disease

Chapter 5 CONSORTIA, GOVERNMENT, AND REGULATORY CONSIDERATIONS

• 5.1. Consortia and Professional Society Involvement
  • Biomarkers Consortium
  • Oncology Biomarker Qualification Initiative (OBQI)
  • Uniform Protocols for Imaging in Clinical Trials (UPICT)
  • Imaging Response Assessment Teams (IRATs)
• 5.2. Government Involvement
  • NIH Molecular Libraries and Imaging Roadmap
  • Network for Translational Research: Optical Imaging (NTROI)
  • Alzheimer' s Disease Neuroimaging Initiative (ADNI)
  • Institute for Molecular Technology (IMT)
  • National Oncologic PET Registry (NOPR)
• 5.3. FDA Regulatory Guidance
• 5.4. National Academy of Sciences Report

Chapter 6 MARKET CONSIDERATIONS

• 6.1. The Molecular Imaging Market Ecology
  • Radiopharmaceuticals
  • Instruments
  • Software
• 6.2. Market Analysis and Dynamics
  • Facilitation of Imaging Agent Development
  • PET Versus SPECT
• 6.3. Drug Discovery and Development Market
  • Large Company Business Models
  • The Convergence of In Vitro and In Vivo Diagnostics
• 6.4. Deals in Molecular Imaging
  • Categorization of Deals
  • Market Size and Growth Projects

Chapter 7 EXPERT INTERVIEWS

• Sudeep Chandra, PhD, General Manager of Molecular Imaging, Philips Healthcare
• Terry A. Colip, Managing Partner and CFO, Cell>Point, LLC
• J. James Frost, MD, PhD, Professor of Radiology and Psychiatry, Yale University, School of Medicine
• Antony Gee, PhD, Director of PET and Radiotracer Development, GlaxoSmithKline
• Franz Hefti, PhD, Chief Scientific Officer, Avid Radiopharmaceuticals
• Patrick McConville, PhD, Director of Imaging, MIR Preclinical Services
• Jean-Luc Vanderheyden, PhD, Global Molecular Imaging Leader, GE Healthcare

APPENDIX

• INSIGHT PHARMA REPORTS MOLECULAR IMAGING SURVEY-OCTOBER 2007
• Observations from the Survey

References

• Company Index with Web Addresses